| Name | Title | Contact Details |
|---|
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.
The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.
CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.
R-Research is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.